{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:29:56Z","timestamp":1790188196666,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1245\/s10434-024-16546-5","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:33:01Z","timestamp":1733157181000},"page":"1784-1794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Multicenter Retrospective Study on Adjuvant S-1 Chemotherapy Versus Observation Following Major Hepatectomy for Perihilar Cholangiocarcinoma"],"prefix":"10.1245","volume":"32","author":[{"given":"Isamu","family":"Hosokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Takayashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusei","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetsugu","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Yabushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"16546_CR1","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1245\/s10434-008-0003-2","volume":"15","author":"I Endo","year":"2008","unstructured":"Endo I, House MG, Klimstra DS, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15:2104\u201312.","journal-title":"Ann Surg Oncol"},{"key":"16546_CR2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1097\/SLA.0000000000000584","volume":"259","author":"I Hosokawa","year":"2014","unstructured":"Hosokawa I, Shimizu H, Yoshidome H, et al. Surgical strategy for hilar cholangiocarcinoma of the left-side predominance: current role of left trisectionectomy. Ann Surg. 2014;259:1178\u201385.","journal-title":"Ann Surg"},{"key":"16546_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/jhbp.481","volume":"24","author":"R Higuchi","year":"2017","unstructured":"Higuchi R, Yazawa T, Uemura S, et al. High-grade dysplasia\/carcinoma in situ of the bile duct margin in patients with surgically resected node-negative perihilar cholangiocarcinoma is associated with poor survival: a retrospective study. J Hepatobiliary Pancreat Sci. 2017;24:456\u201365.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"16546_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/jhbp.1044","volume":"29","author":"I Hosokawa","year":"2022","unstructured":"Hosokawa I, Furukawa K, Takayashiki T, et al. Surgical implications of the confluence patterns of the left intrahepatic bile ducts in right hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2022;29:460\u20138.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"16546_CR5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/SLA.0000000000005103","volume":"274","author":"M Mueller","year":"2021","unstructured":"Mueller M, Breuer E, Mizuno T, et al. Perihilar cholangiocarcinoma \u2013 novel benchmark values for surgical and oncological outcomes from 24 expert centers. Ann Surg. 2021;274:780\u20138.","journal-title":"Ann Surg"},{"issue":"1","key":"16546_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.surg.2023.03.013","volume":"174","author":"I Hosokawa","year":"2023","unstructured":"Hosokawa I, Takayashiki T, Kuboki S, et al. Prognostic impact of proximal ductal margin status in perihilar cholangiocarcinoma according to the presence or absence of lymph node metastasis. Surgery. 2023;174(1):11\u201320.","journal-title":"Surgery"},{"key":"16546_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192\u2013202.","journal-title":"Br J Surg"},{"key":"16546_CR8","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCOD 18-UNICEANCER GI): a randomized phase III study. J Clin Oncol. 2019;37:658\u201367.","journal-title":"J Clin Oncol"},{"key":"16546_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373.","journal-title":"Lancet Oncol"},{"key":"16546_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015\u201327.","journal-title":"J Clin Oncol"},{"key":"16546_CR11","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40:2048\u201357.","journal-title":"J Clin Oncol"},{"key":"16546_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomized, controlled, phase 3 trial. Lancet. 2023;401:195\u2013203.","journal-title":"Lancet"},{"key":"16546_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"16546_CR14","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1245\/s10434-021-11206-4","volume":"29","author":"R Matsuyama","year":"2022","unstructured":"Matsuyama R, Mori R, Ota Y, et al. Impact of gemcitabine plus S1 neoadjuvant chemotherapy on borderline resectable perihilar cholangiocarcinoma. Ann Surg Oncol. 2022;29:2393\u2013405.","journal-title":"Ann Surg Oncol"},{"key":"16546_CR15","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C, et al. TNM classification of malignant tumours. 8th edn. Oxford: Wiley Blackwell; 2017.","edition":"8"},{"key":"16546_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"16546_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.surg.2010.10.001","volume":"149","author":"NN Rahbari","year":"2011","unstructured":"Rahbari NN, Garden OJ, Padbury R, et al. Post hepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713\u201324.","journal-title":"Surgery"},{"key":"16546_CR18","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s10147-018-1283-6","volume":"23","author":"K Nakachi","year":"2018","unstructured":"Nakachi K, Konishi M, Ikeda M, et al. Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. Int J Clin Oncol. 2018;23:894\u20139.","journal-title":"Int J Clin Oncol"},{"key":"16546_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.hpb.2018.08.017","volume":"21","author":"I Hosokawa","year":"2019","unstructured":"Hosokawa I, Shimizu H, Yoshitomi H, et al. Outcomes of left trisectionectomy and right hepatectomy for perihilar cholangiocarcinoma. HPB. 2019;21:489\u201398.","journal-title":"HPB"},{"key":"16546_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/jso.24836","volume":"117","author":"BA Krasnick","year":"2018","unstructured":"Krasnick BA, Jin LX, Davidson JT 4th, et al. Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: a multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol. 2018;117:363\u20133715.","journal-title":"J Surg Oncol"},{"key":"16546_CR21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00595-016-1354-0","volume":"47","author":"T Mizuno","year":"2017","unstructured":"Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resected perihilar cholangiocarcinoma with lymph node involvement: a propensity score matched analysis. Surg Today. 2017;47:182\u201392.","journal-title":"Surg Today"},{"key":"16546_CR22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/jhbp.1005","volume":"28","author":"D Takahashi","year":"2021","unstructured":"Takahashi D, Mizuno T, Yokoyama Y, et al. Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: a propensity score-adjusted analysis. J Hepatobiliary Pancreat Sci. 2021;28:716\u201326.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"16546_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0140-6736(22)02323-6","volume":"401","author":"NJ Chiang","year":"2023","unstructured":"Chiang NJ, Chen LT. Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning. Lancet. 2023;401:170\u20131.","journal-title":"Lancet"},{"key":"16546_CR24","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1093\/annonc\/mdx122","volume":"28","author":"JJM Kwakman","year":"2017","unstructured":"Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol. 2017;28:1288\u201393.","journal-title":"Ann Oncol"},{"key":"16546_CR25","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"O Do-Youn","year":"2022","unstructured":"Do-Youn O, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"16546_CR26","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","volume":"77","author":"H Jeong","year":"2023","unstructured":"Jeong H, Kim KP, Jeong JH, et al. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology. 2023;77:1540\u20139.","journal-title":"Hepatology"},{"key":"16546_CR27","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","volume":"15","author":"A Stein","year":"2015","unstructured":"Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial): randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564.","journal-title":"BMC Cancer"}],"updated-by":[{"DOI":"10.1245\/s10434-024-16817-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000}}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16546-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16546-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16546-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T13:39:04Z","timestamp":1739194744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16546-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["16546"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16546-5","relation":{"correction":[{"id-type":"doi","id":"10.1245\/s10434-024-16817-1","asserted-by":"object"}]},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1245\/s10434-024-16817-1","URL":"https:\/\/doi.org\/10.1245\/s10434-024-16817-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Isamu Hosokawa, Ryota Higuchi, Yuki Homma, Tsukasa Takayashiki, Yusuke Ome, Ryusei Matsuyama, Shigetsugu Takano, Shuichiro Uemura, Yasuhiro Yabushita, Goro Honda, Itaru Endo, and Masayuki Ohtsuka declare they have no conflicts of interest that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}